By Fineline Cube 
CARsgen Therapeutics Holdings Limited (HKG: 2171) has announced its 2025 Interim Results, highlighting significant progress in its CAR T-cell therapy development and commercialization efforts. The company reported cash and bank balances of approximately RMB 1,261 million as of June 30, 2025. Cash and cash equivalents and deposits are expected to remain above RMB 1,100 million by the end of 2025, providing sufficient liquidity to support operations into 2028, excluding subsequent cash inflows.
Regulatory and Commercialization Updates
During the first half of 2025, CARsgen completed certification and regulatory filings for its BCMA CAR-T product, Zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), in over 20 provinces and cities. The company has received a total of 111 confirmed orders from its commercialization partner, Huadong Medicine.
The New Drug Application (NDA) for Satricabtagene autoleucel (satri-cel, R&D code: CT041), an autologous humanized CAR T-cell product targeting Claudin18.2 (CLDN18.2), has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA).
Strategic Partnerships
CARsgen has introduced Zhuhai SB Xinchuang to accelerate the development of allogeneic CAR-T therapies in mainland China. This move underscores the company’s commitment to expanding its product pipeline and enhancing its market presence in the CAR T-cell therapy space.-Fineline Info & Tech